<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3747">
  <stage>Registered</stage>
  <submitdate>14/09/2012</submitdate>
  <approvaldate>14/09/2012</approvaldate>
  <nctid>NCT01689246</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease</studytitle>
    <scientifictitle>Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TRx-237-015</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TRx0237 150 mg/day
Treatment: drugs - TRx0237 250 mg/day
Treatment: drugs - Placebo

Experimental: TRx0237 250 mg/day - 

Placebo Comparator: Placebo - 

Experimental: TRx0237 150 mg/day - 


Treatment: drugs: TRx0237 150 mg/day
TRx0237 75 mg tablets will be administered twice daily.

Treatment: drugs: TRx0237 250 mg/day
TRx0237 125 mg tablets will be administered twice daily.

Treatment: drugs: Placebo
Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from Baseline on Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)</outcome>
      <timepoint>65 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)</outcome>
      <timepoint>65 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes - Safety parameters include adverse events, vital signs, methemoglobin and oxygen saturation, physical and neurological examinations, laboratory tests (hematology, serum chemistry, and urinalysis), electrocardiograms, potential for suicide and self-harm, brain magnetic resonance imaging (MRI), and potential for serotonin toxicity</outcome>
      <timepoint>65 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline on Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)</outcome>
      <timepoint>65 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline on Mini-Mental Status Examination (MMSE)</outcome>
      <timepoint>65 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in expected decline of whole brain volume as measured by brain MRI</outcome>
      <timepoint>39 weeks and 65 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of all cause dementia and probable Alzheimer's disease

          -  Clinical Dementia Rating (CDR) total score of 1 (mild) to 2 (moderate) and MMSE score
             of 14-26 (inclusive)

          -  Age &lt; 90 years

          -  Modified Hachinski ischemic score of = 4

          -  Females, if of child-bearing potential, must practice true abstinence or be competent
             to use adequate contraception and agree to maintain this throughout the study

          -  Subject, and/or, in the case of reduced decision-making capacity, legally acceptable
             representative(s) consistent with national law is/are able to read, understand, and
             provide written informed consent

          -  Has one (or more) identified adult caregiver who is willing to provide written
             informed consent for his/her own participation; is able to read, understand, and speak
             the designated language at the study site; either lives with the subject or sees the
             subject for =2 hours/day =3 days/week; agrees to accompany the subject to each study
             visit; and is able to verify daily compliance with study drug

          -  If currently taking an acetylcholinesterase inhibitor and/or memantine at the time of
             Screening, the subject must have been taking such medication(s) for =3 months. The
             dosage regimen must have remained stable for =6 weeks and it must be planned to remain
             stable throughout participation in the study.

          -  Able to comply with the study procedures</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>89</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Significant central nervous system (CNS) disorder other than Alzheimer's disease

          -  Significant focal or vascular intracranial pathology seen on brain MRI scan

          -  Clinical evidence or history of stroke, transient ischemic attack, significant head
             injury or other unexplained or recurrent loss of consciousness =15 minutes

          -  Epilepsy

          -  Major depressive disorder, schizophrenia, or other psychotic disorders, bipolar
             disorder, or substance (including alcohol) related disorders

          -  Metal implants in the head (except dental), pacemaker, cochlear implants, or any other
             non-removable items that are contraindications to MRI

          -  Resides in hospital or moderate to high dependency continuous care facility

          -  History of swallowing difficulties

          -  Pregnant or breastfeeding

          -  Glucose-6-phosphate dehydrogenase deficiency

          -  History of significant hematological abnormality or current acute or chronic
             clinically significant abnormality

          -  Abnormal serum chemistry laboratory value at Screening deemed to be clinically
             relevant by the investigator

          -  Clinically significant cardiovascular disease or abnormal assessments

          -  Preexisting or current signs or symptoms of respiratory failure

          -  Concurrent acute or chronic clinically significant immunologic, hepatic, or endocrine
             disease (not adequately treated) and/or other unstable or major disease other than
             Alzheimer's disease

          -  Diagnosis of cancer within the past 2 years prior to Baseline (other than basal cell
             or squamous cell skin cancer or Stage 1 prostate cancer) unless treatment has resulted
             in complete freedom from disease for at least 2 years

          -  Prior intolerance or hypersensitivity to methylthioninium-containing drug, similar
             organic dyes, or any of the excipients

          -  Treatment currently or within 3 months before Baseline with any of the following
             medications:

               -  Tacrine

               -  Clozapine, olanzapine (and there is no intent to initiate therapy during the
                  course of the study)

               -  Carbamazepine, primidone

               -  Drugs with a warning or precaution in the labeling about methemoglobinemia at
                  approved doses

          -  Current or prior participation in a clinical trial as follows:

               -  Clinical trial of a product for cognition within 3 months of Screening (unless
                  confirmed to have been randomized to placebo)

               -  A clinical trial of a drug, biologic, therapeutic device, or medical food in
                  which the last dose/administration was received within 28 days prior to Baseline</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>891</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Division of Rehabilitation and Aged Care - Hornsby</hospital>
    <hospital>Southern Neurology Pty Limited - Kogarah</hospital>
    <hospital>Academic Department for Old Age Psychiatry, Prince of Wales Hospital - Randwick</hospital>
    <hospital>Discipline of Psychiatry, University of Qld - Herston</hospital>
    <hospital>Royal Adelaide Hospital Memory Trials Centre - Adelaide</hospital>
    <hospital>Memory Unit, Neurology, The Queen Elizabeth Hospital - Woodville South</hospital>
    <hospital>Medical and Cognitive Research Unit, Austin Health Heidelberg Repatriation Hospital - Heidelberg West</hospital>
    <hospital>McCusker Alzheimer's Research Foundation Inc - Nedlands</hospital>
    <hospital>Neurodegenerative Disorders Research Pty Ltd - Perth</hospital>
    <postcode>2077 - Hornsby</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>4006 - Herston</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5011 - Woodville South</postcode>
    <postcode>3081 - Heidelberg West</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>6005 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Achim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Perugia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Udine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Varese</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seongnam-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Ipoh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Johor Bahru</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Taiping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Mosina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Arad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Brasov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Oradea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Sibiu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ekaterinburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Novosibirsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Ceuta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>CÃ³rdoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Zaragoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Aberdeen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bath</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Belfast</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Blackpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bradford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cannock</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>TauRx Therapeutics Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment
      of subjects with mild to moderate Alzheimer's Disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01689246</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>